Astrocyte Pharmaceuticals Receives NIH Award to Evaluate AST-004 in Substance Use Disorders$400,000 program extends AST-004 into another major CNS indication and reinforces the breadth of its cerebroprotective potential
Astrocyte Pharmaceuticals Announces Milestones in the Fight Against Concussions: Launch of Phase 2 Clinical Trial and New $3M NIH GrantGROTON, Conn., June 17, 2025 (GLOBE NEWSWIRE) -- Astrocyte Pharmaceuticals Inc., a clinical-stage biotechnology company today announced two major milestones that could change the way we protect brains from the damage caused by concussions and repeat head impacts - one of the most pressing health concerns for athletes, military personnel, and families around the world.
